TY - JOUR
T1 - The Multifaceted Burden of Respiratory Syncytial Virus (RSV) Infections in Young Children on the Family
T2 - A European Study
AU - Trautmannsberger, Ilona
AU - Plagg, Barbara
AU - Adamek, Ina
AU - Mader, Silke
AU - de Luca, Daniele
AU - Esposito, Susanna
AU - Silfverdal, Sven Arne
AU - Zimmermann, Luc J. I.
AU - Tischer, Christina
AU - ResQ Family Study Group
PY - 2024/7
Y1 - 2024/7
N2 - Introduction: Since the majority of hospitalisations due to RSV occur in young children, the illness profoundly influences the entire family. However, comprehensive evidence regarding its overall effects remains limited. The ResQ Family study aims to investigate the burden of RSV-induced pediatric hospitalisation on affected families. Methods: Spanning the 2022–2023 RSV season, an interdisciplinary, observational study was conducted in Germany, France, Italy and Sweden. Using an online questionnaire, parents and caregivers of children (< 24 months of age) with an RSV-induced hospitalisation were recruited. Information was gathered on topics related to RSV and parental health-related quality of life (HRQoL) during the acute infection phase (t0) and 6 weeks later (t1). Descriptive evaluations of the data set were performed during t0 and regarding a potential change over the observation period (t0 vs. t1). Subgroup analysis aimed to further identify differences across the countries. Results: A total set of 138 affected parents/caregivers were included in the study, with 59 participants responding to the follow-up survey (t1). Particularly during the acute infection phase, parental HRQoL was shown to be negatively influenced by the child’s RSV infection [total score (p < 0.001, d = 0.54), parent HRQoL summary score (p < 0.001, d = 0.67) and family functioning summary score (p = 0.007, d = 0.33)]. Significant disparities in disease awareness and support structures were observed across Europe, with France and Sweden showing notably higher levels. Conclusion: The ResQ Family study provides convincing evidence that RSV-associated hospitalisations in young children across Europe generate a multifaced burden for the entire family, partly even beyond the acute infection phase. Standardised approaches for disease prevention at societal, educational and policy levels are needed to guarantee every newborn the best possible start into life. Trial Registration: ClinicalTrials.gov, identifier, NCT05550545.
AB - Introduction: Since the majority of hospitalisations due to RSV occur in young children, the illness profoundly influences the entire family. However, comprehensive evidence regarding its overall effects remains limited. The ResQ Family study aims to investigate the burden of RSV-induced pediatric hospitalisation on affected families. Methods: Spanning the 2022–2023 RSV season, an interdisciplinary, observational study was conducted in Germany, France, Italy and Sweden. Using an online questionnaire, parents and caregivers of children (< 24 months of age) with an RSV-induced hospitalisation were recruited. Information was gathered on topics related to RSV and parental health-related quality of life (HRQoL) during the acute infection phase (t0) and 6 weeks later (t1). Descriptive evaluations of the data set were performed during t0 and regarding a potential change over the observation period (t0 vs. t1). Subgroup analysis aimed to further identify differences across the countries. Results: A total set of 138 affected parents/caregivers were included in the study, with 59 participants responding to the follow-up survey (t1). Particularly during the acute infection phase, parental HRQoL was shown to be negatively influenced by the child’s RSV infection [total score (p < 0.001, d = 0.54), parent HRQoL summary score (p < 0.001, d = 0.67) and family functioning summary score (p = 0.007, d = 0.33)]. Significant disparities in disease awareness and support structures were observed across Europe, with France and Sweden showing notably higher levels. Conclusion: The ResQ Family study provides convincing evidence that RSV-associated hospitalisations in young children across Europe generate a multifaced burden for the entire family, partly even beyond the acute infection phase. Standardised approaches for disease prevention at societal, educational and policy levels are needed to guarantee every newborn the best possible start into life. Trial Registration: ClinicalTrials.gov, identifier, NCT05550545.
KW - Respiratory syncytial virus (RSV)
KW - Quality of life
KW - HRQoL
KW - Parents
KW - Children
KW - Family
KW - Disease burden
KW - QUALITY-OF-LIFE
KW - UNITED-STATES
KW - HOSPITALIZATION
KW - IMPACT
KW - CAREGIVER
KW - INFLUENZA
KW - PARENTS
U2 - 10.1007/s40121-024-00989-0
DO - 10.1007/s40121-024-00989-0
M3 - Article
SN - 2193-8229
VL - 13
SP - 1531
EP - 1573
JO - Infectious Diseases and Therapy
JF - Infectious Diseases and Therapy
IS - 7
ER -